Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus

NCT00356421 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00356421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00356421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week Multicenter, Open-Label, Randomized, Parallel, Two - Arm Study Comparing Exubera® (Inhaled Human Insulin) Vs. Humalog® (Insulin Lispro), Both In Combination With Insulin Glargine In Subjects With Type 1 Diabetes Mellitus
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2006
Completion date
June 30, 2008
Enrollment
58 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1